Pharmaceutical giant AstraZeneca’s agreement to sell much of its antibiotics business won’t impact operations at MedImmune, its Gaithersburg-based research and development arm, officials confirmed Wednesday.
{iframe}http://www.bizjournals.com/baltimore/news/2016/08/25/gaithersburg-based-medimmune-wont-be-impacted-by.html?ana=e_me_set2&s=newsletter&ed=2016-08-25&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1472218147&j=75551892{/iframe}